RAPP

Rapport Therapeutics Inc

• PUBT·2d ago

  Rapport Therapeutics shareholders elected Class II directors at annual meeting

• TipRanks·06/04 16:33

  RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy

• TipRanks·06/02 11:19

  BTIG Reaffirms Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

• PUBT·05/28 20:16

  Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $743,673.08

• TipRanks·05/21 11:56

  Rapport Therapeutics, Inc. (RAPP) Receives a Buy from BTIG

• TipRanks·05/21 11:51

  Rapport Therapeutics price target raised to $65 from $53 at BTIG

• Dow Jones·05/21 11:15

  Rapport Therapeutics Is Maintained at Buy by BTIG

• Dow Jones·05/21 11:15

  Rapport Therapeutics Price Target Raised to $65.00/Share From $53.00 by BTIG

• Benzinga·05/21 11:04

  BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $65

• Reuters·05/21 06:42

  U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, Nvidia

• PUBT·05/20 20:07

  Rapport Therapeutics to present at Jefferies Global Healthcare Conference fireside chat

• Dow Jones·05/19 18:42

  Rapport Therapeutics Price Target Raised to $56.00/Share From $44.00 by Truist Securities

• Dow Jones·05/19 18:42

  Rapport Therapeutics Coverage Assumed by Truist Securities at Buy

• Benzinga·05/19 18:32

  Truist Securities Assumes Rapport Therapeutics at Buy, Raises Price Target to $56

• Reuters·05/19 11:10

  RAPPORT THERAPEUTICS INC <RAPP.O>: TRUIST SECURITIES RAISES TARGET PRICE TO $56 FROM $44